Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunohistochemical Expression of SOX2 and PD-L1 as Valuable Prognostic Markers in Urinary Bladder Carcinoma

NCT05429710 is registered in ClinicalTrials.gov with Sohag University as lead sponsor.

NCT NCT05429710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05429710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunohistochemical Expression of SOX2 and PD-L1 as Valuable Prognostic Markers in Urinary Bladder Carcinoma
Lead sponsor
Sohag University
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2022
Completion date
December 1, 2023
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder neoplasm